No data available.
Please log in to see this content.
You have no subscription access to this content.
The full text of this article is not currently available.
Additional Effects of Pranlukast on Exhaled Nitric Oxide Levels in Patients with Persistent Asthma
Rent:
Rent this article for
JPY
Abstract
Background:Leukotriene receptor antagonist(LTRA)and/or long−acting beta2−agonist(LABA)agents are considered as add−on therapy to inhaled corticosteroids(ICS).We aimed to assess the additional effects of pranlukast to combination therapy with ICS and LABA on exhaled nitric oxide(NO)levels in patients with persistent asthma.Methods:Twenty outpatients with mild to severe persistent asthma, who were managed with combination therapy with ICS and inhaled LABA(salmeterol 100μg/day),were given pranlukast(450 mg/day)for 4 weeks as add−on therapy. Exhaled NO measurements and spirometry tests were performed at entry, after add−on therapy period, and after wash−out period.Results:Exhaled NO levels decreased significantly after add−on treatment period [26.6(1.1)ppb at entry, 18.3(1.9)ppb at the end of add−on period, and 21.1(1.1)ppb at the end of wash−out period;geometric means(GSEM)]. FEV1 increased significantly after add−on treatment period[2.08±0.12 L at entry, 2.14±0.56 L on add−on therapy, and 2.08±0.58 L at the end of wash−out period;means±SEM].Conclusion:Our findings indicate that pranlukast inhibits eosinophilic airway inflammation that remains in patients with persistent asthma given combination therapy with ICS and inhaled LABA.
Full text loading...
/content/article/0289-8020/30080/1361